10 November 2016 
EMA/691442/2016  
Human Medicines Evaluation Division 
Statement indicating compliance with the agreed completed 
paediatric investigation plan  
Medicinal product  
Humira/ adalimumab 
Pharmaceutical form(s): 
See Annex A of the CHMP Opinion 
Strength(s): 
See Annex A 
Route(s) of administration: 
See Annex A 
Packaging and package size(s):  See Annex A 
Number(s)in the Community 
See Annex A 
Register of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH:  AbbVie Ltd. 
Abbott House 
Vanwall Business Park 
Vanwall Road 
Maidenhead,  
Berkshire 
SL6 4UB 
UNITED KINGDOM 
Procedure  
Procedure number: 
EMEA/H/C/000481/II/0154 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
- the development of this product has complied with all measures in the agreed paediatric investigation 
plan P/0121/2013. All studies in the agreed paediatric investigation plan P/0121/2013 were conducted 
after the entry into force of that Regulation,  
- the Summary of Product Characteristics reflects the results of studies conducted in compliance with 
this agreed paediatric investigation plan. 
In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance 
with the agreed completed paediatric investigation plan P/0121/2013 is included in the technical 
dossier.  
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5555 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
 
 
 
 
  
